Free Cash Flow

With new data showing six-month efficacy and a unique liquid formula, Galderma's Relfydess is poised to challenge established players in the neuromodulator space.

Pacer ETFs launches three funds targeting R&D leaders, high-quality dividends, and international exporters, expanding its rules-based, cash-flow-centric toolkit.

A new partnership embeds Nasdaq's institutional data into Juniper Square's AI CRM, promising to end manual work for investor relations teams.

Japanese entertainment firm TryHard Holdings saw its stock surge on a $10M buyback, only to plummet after a conflicting capital deal sparked dilution fears.

The eyecare tech firm reports a strong fourth quarter fueled by its TearCare system, even as full-year results show a slight dip. Is this a turning point?

With Vans in a slump and The North Face soaring, VF Corp's new leadership will detail its strategic vision at a key conference watched by Wall Street.

How the chemical giant navigated a complex SAP migration and divestments, using a cloud solution to secure legacy data and cut significant operational costs.

With a new CEO, a capital markets veteran on its board, and a sweeping strategic review, personal care giant Ontex signals an urgent push for reinvention.

Investors and HR leaders watch as Unum prepares to release its Q4 results and 2026 strategy in a rapidly evolving workplace benefits landscape.

The clean-energy firm is commercializing its tech, securing a 10-year fuel deal in Portugal and deploying rail turbines as it seeks greater market access.

The wellness firm secured a cash infusion by repricing options, a move that provides vital funds for its Zola brand but raises questions about dilution.

Biomea Fusion launches a high-stakes 2026 plan, advancing a novel diabetes drug to restore insulin cells and an oral pill to rival obesity giants.

A new White House executive order and a proposed $1.5T budget are shaking up defense contracting. Here's how agile firms like Volatus are set to win.

With its new thalassemia drug AQVESME launching, Agios aims for blockbuster status while navigating a key safety warning and advancing a broad pipeline.

The pediatric device firm posted 15% growth to $236.1M in 2025, issuing strong 2026 guidance fueled by its specialty bracing and European expansion.

The firm gives bondholders more time to trade near-term notes for a higher yield, sparking debate on strategy versus necessity in a tough market.

FIS finalizes its $12B acquisition of Global Payments' issuer arm and sells its Worldpay stake, creating a new data-driven force in banking tech.

EfTEN Real Estate Fund reports its best-ever operating results, proposing an 8% dividend hike, while a minor portfolio revaluation hints at market shifts.

At CES 2026, Jinxin Technology unveiled NAMI INSIGHT One, AI-powered learning glasses aiming to revolutionize education. But can it overcome the hurdles?

EpicQuest Education's CES award highlights its AI university plans, but a closer look reveals a complex picture of innovation, market hype, and financial risk.